Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence

Phase 3

Terminated

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Combination Product: Concept2 inhaler with patient application
Combination Product: Concept2 inhaler

First Posted Date: 2017-12-20

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT03379233

Locations: 🇳🇱
Novartis Investigative Site, Zutphen, Netherlands

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

Phase 2

Withdrawn

Conditions: Complicated Urinary Tract Infections

Interventions: Drug: Standard of care therapy
Drug: LYS228

First Posted Date: 2017-12-19

Last Posted Date: 2018-10-26

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03377426

Locations: 🇬🇷
Novartis Investigative Site, Athens, Greece

A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa

Phase 1

Active, not recruiting

Conditions: Retinitis Pigmentosa

Interventions: Biological: CPK850

First Posted Date: 2017-12-15

Last Posted Date: 2025-01-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT03374657

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Phase 2

Completed

Conditions: IgA Nephropathy

Interventions: Other: Placebo
Drug: LNP023

First Posted Date: 2017-12-14

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 112

Registration Number: NCT03373461

Locations: 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

Phase 4

Completed

Conditions: Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2017-12-13

Last Posted Date: 2020-08-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT03372083

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

Phase 2

Withdrawn

Conditions: HCMV Infection

Interventions: Biological: CSJ148
Other: Placebo

First Posted Date: 2017-12-12

Last Posted Date: 2018-10-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03369912

Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Omalizumab
Drug: Placebo

First Posted Date: 2017-12-12

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 337

Registration Number: NCT03369704

Locations: 🇯🇵
Novartis Investigative Site, Toshima-Ku, Tokyo, Japan

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Phase 2

Completed

Conditions: Ovarian Adenocarcinoma
Castration Resistant Prostate Adenocarcinoma
Advanced Well-differentiated Neuroendocrine Tumors
Gastric Adenocarcinoma
Small Cell Lung Cancer
Soft Tissue Sarcoma
Diffuse Large B Cell Lymphoma
Esophageal Adenocarcinoma

Interventions: Biological: PDR001
Biological: LAG525

First Posted Date: 2017-12-07

Last Posted Date: 2022-05-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT03365791

Locations: 🇺🇸
Northwestern University Medical School, Chicago, Illinois, United States
🇺🇸
University of Illinois Cancer Center at Chicago SC, Chicago, Illinois, United States
🇺🇸
Oncology Consultants Oncology Consultants, Houston, Texas, United States

and more 17 locations

First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients

Phase 1

Completed

Conditions: Patients With Moderate Knee Osteoarthritis (30 - 65 Years)

Interventions: Drug: Placebo
Drug: LRX712

First Posted Date: 2017-11-28

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT03355196

Locations: 🇳🇱
Novartis Investigative Site, Leiden, Netherlands

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

Phase 2

Terminated

Conditions: Intra-abdominal Infections

Interventions: Drug: Standard of care therapy
Drug: LYS228

First Posted Date: 2017-11-28

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT03354754

Locations: 🇺🇸
Novartis Investigative Site, Somers Point, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy